nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—Angiotensin 2 Receptor Antagonists—Valsartan—type 2 diabetes mellitus	0.134	0.5	CiPCiCtD
Irbesartan—Angiotensin 2 Receptor Antagonists—Losartan—type 2 diabetes mellitus	0.134	0.5	CiPCiCtD
Irbesartan—hypertension—type 2 diabetes mellitus	0.125	1	CtDrD
Irbesartan—Valsartan—type 2 diabetes mellitus	0.11	0.54	CrCtD
Irbesartan—Losartan—type 2 diabetes mellitus	0.0936	0.46	CrCtD
Irbesartan—EDNRA—type 2 diabetes mellitus	0.0656	0.688	CbGaD
Irbesartan—AGTR1—Valsartan—type 2 diabetes mellitus	0.0202	0.178	CbGbCtD
Irbesartan—CYP1A2—type 2 diabetes mellitus	0.018	0.188	CbGaD
Irbesartan—Forasartan—Valsartan—type 2 diabetes mellitus	0.0168	0.129	CrCrCtD
Irbesartan—Tasosartan—Valsartan—type 2 diabetes mellitus	0.0149	0.114	CrCrCtD
Irbesartan—Valsartan—Losartan—type 2 diabetes mellitus	0.0143	0.11	CrCrCtD
Irbesartan—Forasartan—Losartan—type 2 diabetes mellitus	0.0143	0.11	CrCrCtD
Irbesartan—Olmesartan—Valsartan—type 2 diabetes mellitus	0.0134	0.102	CrCrCtD
Irbesartan—Tasosartan—Losartan—type 2 diabetes mellitus	0.0127	0.0969	CrCrCtD
Irbesartan—Losartan—Valsartan—type 2 diabetes mellitus	0.0122	0.0932	CrCrCtD
Irbesartan—CYP3A4—type 2 diabetes mellitus	0.0119	0.125	CbGaD
Irbesartan—AGTR1—Losartan—type 2 diabetes mellitus	0.0116	0.102	CbGbCtD
Irbesartan—Olmesartan—Losartan—type 2 diabetes mellitus	0.0114	0.0871	CrCrCtD
Irbesartan—Candesartan—Valsartan—type 2 diabetes mellitus	0.0112	0.0857	CrCrCtD
Irbesartan—Candesartan—Losartan—type 2 diabetes mellitus	0.00951	0.0728	CrCrCtD
Irbesartan—UGT1A3—Losartan—type 2 diabetes mellitus	0.00718	0.0635	CbGbCtD
Irbesartan—PTGS1—Chlorpropamide—type 2 diabetes mellitus	0.00486	0.043	CbGbCtD
Irbesartan—PTGS1—Pioglitazone—type 2 diabetes mellitus	0.00486	0.043	CbGbCtD
Irbesartan—PTGS1—Rosiglitazone—type 2 diabetes mellitus	0.00449	0.0397	CbGbCtD
Irbesartan—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.00388	0.0343	CbGbCtD
Irbesartan—PTGS1—Nateglinide—type 2 diabetes mellitus	0.00369	0.0326	CbGbCtD
Irbesartan—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.0031	0.0275	CbGbCtD
Irbesartan—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.00281	0.0248	CbGbCtD
Irbesartan—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.00271	0.024	CbGbCtD
Irbesartan—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.00259	0.0229	CbGbCtD
Irbesartan—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.0025	0.0221	CbGbCtD
Irbesartan—CYP2C9—Glipizide—type 2 diabetes mellitus	0.00248	0.0219	CbGbCtD
Irbesartan—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.0023	0.0204	CbGbCtD
Irbesartan—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.002	0.0177	CbGbCtD
Irbesartan—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.00196	0.0173	CbGbCtD
Irbesartan—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.00196	0.0173	CbGbCtD
Irbesartan—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.00181	0.016	CbGbCtD
Irbesartan—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00179	0.0158	CbGbCtD
Irbesartan—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00177	0.0156	CbGbCtD
Irbesartan—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.00174	0.0154	CbGbCtD
Irbesartan—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00165	0.0146	CbGbCtD
Irbesartan—CYP2C9—Valsartan—type 2 diabetes mellitus	0.0016	0.0141	CbGbCtD
Irbesartan—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00157	0.0139	CbGbCtD
Irbesartan—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00149	0.0132	CbGbCtD
Irbesartan—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.00148	0.0131	CbGbCtD
Irbesartan—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00144	0.0127	CbGbCtD
Irbesartan—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00136	0.012	CbGbCtD
Irbesartan—CYP2C8—Losartan—type 2 diabetes mellitus	0.00131	0.0116	CbGbCtD
Irbesartan—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00126	0.0111	CbGbCtD
Irbesartan—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00114	0.0101	CbGbCtD
Irbesartan—CYP1A2—Losartan—type 2 diabetes mellitus	0.00102	0.009	CbGbCtD
Irbesartan—CYP2C9—Glyburide—type 2 diabetes mellitus	0.001	0.00886	CbGbCtD
Irbesartan—CYP2C9—Losartan—type 2 diabetes mellitus	0.000916	0.00811	CbGbCtD
Irbesartan—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.000862	0.00763	CbGbCtD
Irbesartan—CYP3A4—Orlistat—type 2 diabetes mellitus	0.000827	0.00732	CbGbCtD
Irbesartan—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.000782	0.00692	CbGbCtD
Irbesartan—JUN—peripheral nervous system—type 2 diabetes mellitus	0.000677	0.0983	CbGeAlD
Irbesartan—CYP3A4—Glyburide—type 2 diabetes mellitus	0.000583	0.00515	CbGbCtD
Irbesartan—CYP3A4—Losartan—type 2 diabetes mellitus	0.000533	0.00471	CbGbCtD
Irbesartan—JUN—artery—type 2 diabetes mellitus	0.000532	0.0773	CbGeAlD
Irbesartan—JUN—nerve—type 2 diabetes mellitus	0.000528	0.0767	CbGeAlD
Irbesartan—Tasosartan—AGTR2—type 2 diabetes mellitus	0.000489	0.639	CrCbGaD
Irbesartan—JUN—endothelium—type 2 diabetes mellitus	0.00045	0.0653	CbGeAlD
Irbesartan—AGTR1—artery—type 2 diabetes mellitus	0.000401	0.0582	CbGeAlD
Irbesartan—AGTR1—endothelium—type 2 diabetes mellitus	0.000339	0.0492	CbGeAlD
Irbesartan—JUN—islet of Langerhans—type 2 diabetes mellitus	0.000256	0.0371	CbGeAlD
Irbesartan—JUN—retina—type 2 diabetes mellitus	0.000219	0.0317	CbGeAlD
Irbesartan—JUN—nephron tubule—type 2 diabetes mellitus	0.000206	0.0299	CbGeAlD
Irbesartan—UGT1A3—liver—type 2 diabetes mellitus	0.000202	0.0293	CbGeAlD
Irbesartan—EDNRA—cortex of kidney—type 2 diabetes mellitus	0.000193	0.028	CbGeAlD
Irbesartan—JUN—cardiovascular system—type 2 diabetes mellitus	0.000185	0.0269	CbGeAlD
Irbesartan—JUN—kidney—type 2 diabetes mellitus	0.000181	0.0263	CbGeAlD
Irbesartan—JUN—pancreas—type 2 diabetes mellitus	0.00018	0.0261	CbGeAlD
Irbesartan—EDNRA—adipose tissue—type 2 diabetes mellitus	0.000179	0.026	CbGeAlD
Irbesartan—JUN—cortex of kidney—type 2 diabetes mellitus	0.000176	0.0256	CbGeAlD
Irbesartan—PTGS1—artery—type 2 diabetes mellitus	0.000176	0.0256	CbGeAlD
Irbesartan—JUN—adipose tissue—type 2 diabetes mellitus	0.000163	0.0237	CbGeAlD
Irbesartan—AGTR1—nephron tubule—type 2 diabetes mellitus	0.000155	0.0225	CbGeAlD
Irbesartan—PTGS1—endothelium—type 2 diabetes mellitus	0.000149	0.0216	CbGeAlD
Irbesartan—AGTR1—cardiovascular system—type 2 diabetes mellitus	0.000139	0.0202	CbGeAlD
Irbesartan—AGTR1—kidney—type 2 diabetes mellitus	0.000136	0.0198	CbGeAlD
Irbesartan—AGTR1—cortex of kidney—type 2 diabetes mellitus	0.000133	0.0193	CbGeAlD
Irbesartan—AGTR1—adipose tissue—type 2 diabetes mellitus	0.000123	0.0178	CbGeAlD
Irbesartan—JUN—liver—type 2 diabetes mellitus	0.000114	0.0166	CbGeAlD
Irbesartan—Olmesartan—ABCC2—type 2 diabetes mellitus	8.79e-05	0.115	CrCbGaD
Irbesartan—AGTR1—liver—type 2 diabetes mellitus	8.62e-05	0.0125	CbGeAlD
Irbesartan—CYP2C8—kidney—type 2 diabetes mellitus	7.39e-05	0.0107	CbGeAlD
Irbesartan—CYP2C9—cardiovascular system—type 2 diabetes mellitus	6.71e-05	0.00974	CbGeAlD
Irbesartan—PTGS1—cardiovascular system—type 2 diabetes mellitus	6.13e-05	0.00889	CbGeAlD
Irbesartan—PTGS1—kidney—type 2 diabetes mellitus	5.99e-05	0.0087	CbGeAlD
Irbesartan—PTGS1—adipose tissue—type 2 diabetes mellitus	5.4e-05	0.00784	CbGeAlD
Irbesartan—CYP3A4—kidney—type 2 diabetes mellitus	5.01e-05	0.00727	CbGeAlD
Irbesartan—CYP2D6—kidney—type 2 diabetes mellitus	4.93e-05	0.00715	CbGeAlD
Irbesartan—CYP2C8—liver—type 2 diabetes mellitus	4.67e-05	0.00678	CbGeAlD
Irbesartan—Tasosartan—CYP3A4—type 2 diabetes mellitus	4.6e-05	0.0601	CrCbGaD
Irbesartan—CYP1A2—liver—type 2 diabetes mellitus	4.37e-05	0.00635	CbGeAlD
Irbesartan—CYP2C9—liver—type 2 diabetes mellitus	4.15e-05	0.00602	CbGeAlD
Irbesartan—Losartan—ACE—type 2 diabetes mellitus	4.15e-05	0.0542	CrCbGaD
Irbesartan—Valsartan—ALB—type 2 diabetes mellitus	3.48e-05	0.0455	CrCbGaD
Irbesartan—CYP3A4—liver—type 2 diabetes mellitus	3.16e-05	0.00459	CbGeAlD
Irbesartan—CYP2D6—liver—type 2 diabetes mellitus	3.11e-05	0.00452	CbGeAlD
Irbesartan—Losartan—CYP1A2—type 2 diabetes mellitus	2.94e-05	0.0384	CrCbGaD
Irbesartan—Losartan—CYP3A4—type 2 diabetes mellitus	1.95e-05	0.0254	CrCbGaD
Irbesartan—Losartan—ALB—type 2 diabetes mellitus	1.7e-05	0.0222	CrCbGaD
Irbesartan—Skin disorder—Orlistat—type 2 diabetes mellitus	1.38e-05	0.000393	CcSEcCtD
Irbesartan—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	1.38e-05	0.000393	CcSEcCtD
Irbesartan—Abdominal pain—Glyburide—type 2 diabetes mellitus	1.38e-05	0.000393	CcSEcCtD
Irbesartan—Dyspepsia—Gliclazide—type 2 diabetes mellitus	1.38e-05	0.000393	CcSEcCtD
Irbesartan—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	1.37e-05	0.000391	CcSEcCtD
Irbesartan—Anorexia—Valsartan—type 2 diabetes mellitus	1.37e-05	0.000391	CcSEcCtD
Irbesartan—Muscle spasms—Losartan—type 2 diabetes mellitus	1.37e-05	0.00039	CcSEcCtD
Irbesartan—Asthenia—Bromocriptine—type 2 diabetes mellitus	1.37e-05	0.00039	CcSEcCtD
Irbesartan—Chest pain—Metformin—type 2 diabetes mellitus	1.36e-05	0.000389	CcSEcCtD
Irbesartan—Myalgia—Metformin—type 2 diabetes mellitus	1.36e-05	0.000389	CcSEcCtD
Irbesartan—Headache—Pioglitazone—type 2 diabetes mellitus	1.36e-05	0.000387	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	1.35e-05	0.000387	CcSEcCtD
Irbesartan—Visual impairment—Ramipril—type 2 diabetes mellitus	1.35e-05	0.000386	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	1.35e-05	0.000385	CcSEcCtD
Irbesartan—Discomfort—Metformin—type 2 diabetes mellitus	1.35e-05	0.000385	CcSEcCtD
Irbesartan—Fatigue—Gliclazide—type 2 diabetes mellitus	1.35e-05	0.000385	CcSEcCtD
Irbesartan—Nausea—Glipizide—type 2 diabetes mellitus	1.34e-05	0.000383	CcSEcCtD
Irbesartan—Vomiting—Glimepiride—type 2 diabetes mellitus	1.34e-05	0.000383	CcSEcCtD
Irbesartan—Hypotension—Valsartan—type 2 diabetes mellitus	1.34e-05	0.000383	CcSEcCtD
Irbesartan—Vision blurred—Losartan—type 2 diabetes mellitus	1.34e-05	0.000383	CcSEcCtD
Irbesartan—Vomiting—Sitagliptin—type 2 diabetes mellitus	1.34e-05	0.000382	CcSEcCtD
Irbesartan—Pain—Gliclazide—type 2 diabetes mellitus	1.34e-05	0.000381	CcSEcCtD
Irbesartan—Constipation—Gliclazide—type 2 diabetes mellitus	1.34e-05	0.000381	CcSEcCtD
Irbesartan—Tremor—Losartan—type 2 diabetes mellitus	1.33e-05	0.00038	CcSEcCtD
Irbesartan—Rash—Glimepiride—type 2 diabetes mellitus	1.33e-05	0.00038	CcSEcCtD
Irbesartan—Dermatitis—Glimepiride—type 2 diabetes mellitus	1.33e-05	0.000379	CcSEcCtD
Irbesartan—Rash—Sitagliptin—type 2 diabetes mellitus	1.33e-05	0.000379	CcSEcCtD
Irbesartan—Dermatitis—Sitagliptin—type 2 diabetes mellitus	1.33e-05	0.000378	CcSEcCtD
Irbesartan—Headache—Glimepiride—type 2 diabetes mellitus	1.32e-05	0.000377	CcSEcCtD
Irbesartan—Ill-defined disorder—Losartan—type 2 diabetes mellitus	1.32e-05	0.000377	CcSEcCtD
Irbesartan—Headache—Sitagliptin—type 2 diabetes mellitus	1.32e-05	0.000376	CcSEcCtD
Irbesartan—Anaemia—Losartan—type 2 diabetes mellitus	1.32e-05	0.000375	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	1.31e-05	0.000373	CcSEcCtD
Irbesartan—Agitation—Losartan—type 2 diabetes mellitus	1.31e-05	0.000373	CcSEcCtD
Irbesartan—Oedema—Metformin—type 2 diabetes mellitus	1.31e-05	0.000373	CcSEcCtD
Irbesartan—Tinnitus—Ramipril—type 2 diabetes mellitus	1.31e-05	0.000373	CcSEcCtD
Irbesartan—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	1.3e-05	0.000372	CcSEcCtD
Irbesartan—Flushing—Ramipril—type 2 diabetes mellitus	1.3e-05	0.000371	CcSEcCtD
Irbesartan—Angioedema—Losartan—type 2 diabetes mellitus	1.3e-05	0.000371	CcSEcCtD
Irbesartan—Infection—Metformin—type 2 diabetes mellitus	1.3e-05	0.000371	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	1.29e-05	0.000369	CcSEcCtD
Irbesartan—Paraesthesia—Valsartan—type 2 diabetes mellitus	1.29e-05	0.000368	CcSEcCtD
Irbesartan—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	1.29e-05	0.000368	CcSEcCtD
Irbesartan—Shock—Metformin—type 2 diabetes mellitus	1.29e-05	0.000367	CcSEcCtD
Irbesartan—Malaise—Losartan—type 2 diabetes mellitus	1.28e-05	0.000366	CcSEcCtD
Irbesartan—Hypersensitivity—Glyburide—type 2 diabetes mellitus	1.28e-05	0.000366	CcSEcCtD
Irbesartan—Nervous system disorder—Metformin—type 2 diabetes mellitus	1.28e-05	0.000366	CcSEcCtD
Irbesartan—Thrombocytopenia—Metformin—type 2 diabetes mellitus	1.28e-05	0.000365	CcSEcCtD
Irbesartan—Dyspnoea—Valsartan—type 2 diabetes mellitus	1.28e-05	0.000365	CcSEcCtD
Irbesartan—Vertigo—Losartan—type 2 diabetes mellitus	1.28e-05	0.000365	CcSEcCtD
Irbesartan—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	1.28e-05	0.000365	CcSEcCtD
Irbesartan—Somnolence—Valsartan—type 2 diabetes mellitus	1.28e-05	0.000364	CcSEcCtD
Irbesartan—Syncope—Losartan—type 2 diabetes mellitus	1.28e-05	0.000364	CcSEcCtD
Irbesartan—Paraesthesia—Orlistat—type 2 diabetes mellitus	1.27e-05	0.000364	CcSEcCtD
Irbesartan—Leukopenia—Losartan—type 2 diabetes mellitus	1.27e-05	0.000364	CcSEcCtD
Irbesartan—Skin disorder—Metformin—type 2 diabetes mellitus	1.27e-05	0.000363	CcSEcCtD
Irbesartan—Immune system disorder—Ramipril—type 2 diabetes mellitus	1.27e-05	0.000361	CcSEcCtD
Irbesartan—Hyperhidrosis—Metformin—type 2 diabetes mellitus	1.26e-05	0.000361	CcSEcCtD
Irbesartan—Dyspepsia—Valsartan—type 2 diabetes mellitus	1.26e-05	0.000361	CcSEcCtD
Irbesartan—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	1.26e-05	0.000361	CcSEcCtD
Irbesartan—Dizziness—Bromocriptine—type 2 diabetes mellitus	1.26e-05	0.000359	CcSEcCtD
Irbesartan—Nausea—Glimepiride—type 2 diabetes mellitus	1.25e-05	0.000358	CcSEcCtD
Irbesartan—Arrhythmia—Ramipril—type 2 diabetes mellitus	1.25e-05	0.000357	CcSEcCtD
Irbesartan—Loss of consciousness—Losartan—type 2 diabetes mellitus	1.25e-05	0.000357	CcSEcCtD
Irbesartan—Nausea—Sitagliptin—type 2 diabetes mellitus	1.25e-05	0.000357	CcSEcCtD
Irbesartan—Dyspepsia—Orlistat—type 2 diabetes mellitus	1.25e-05	0.000356	CcSEcCtD
Irbesartan—Asthenia—Glyburide—type 2 diabetes mellitus	1.25e-05	0.000356	CcSEcCtD
Irbesartan—Decreased appetite—Valsartan—type 2 diabetes mellitus	1.25e-05	0.000356	CcSEcCtD
Irbesartan—Anorexia—Metformin—type 2 diabetes mellitus	1.25e-05	0.000356	CcSEcCtD
Irbesartan—Cough—Losartan—type 2 diabetes mellitus	1.24e-05	0.000354	CcSEcCtD
Irbesartan—Urticaria—Gliclazide—type 2 diabetes mellitus	1.24e-05	0.000354	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	1.24e-05	0.000354	CcSEcCtD
Irbesartan—Fatigue—Valsartan—type 2 diabetes mellitus	1.24e-05	0.000353	CcSEcCtD
Irbesartan—Body temperature increased—Gliclazide—type 2 diabetes mellitus	1.24e-05	0.000353	CcSEcCtD
Irbesartan—Abdominal pain—Gliclazide—type 2 diabetes mellitus	1.24e-05	0.000353	CcSEcCtD
Irbesartan—Decreased appetite—Orlistat—type 2 diabetes mellitus	1.23e-05	0.000352	CcSEcCtD
Irbesartan—Pruritus—Glyburide—type 2 diabetes mellitus	1.23e-05	0.000351	CcSEcCtD
Irbesartan—Constipation—Valsartan—type 2 diabetes mellitus	1.23e-05	0.00035	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	1.23e-05	0.00035	CcSEcCtD
Irbesartan—Fatigue—Orlistat—type 2 diabetes mellitus	1.22e-05	0.000349	CcSEcCtD
Irbesartan—Hypotension—Metformin—type 2 diabetes mellitus	1.22e-05	0.000349	CcSEcCtD
Irbesartan—Erythema—Ramipril—type 2 diabetes mellitus	1.22e-05	0.000348	CcSEcCtD
Irbesartan—Malnutrition—Ramipril—type 2 diabetes mellitus	1.22e-05	0.000348	CcSEcCtD
Irbesartan—Pain—Orlistat—type 2 diabetes mellitus	1.21e-05	0.000346	CcSEcCtD
Irbesartan—Arthralgia—Losartan—type 2 diabetes mellitus	1.21e-05	0.000346	CcSEcCtD
Irbesartan—Chest pain—Losartan—type 2 diabetes mellitus	1.21e-05	0.000346	CcSEcCtD
Irbesartan—Myalgia—Losartan—type 2 diabetes mellitus	1.21e-05	0.000346	CcSEcCtD
Irbesartan—Vomiting—Bromocriptine—type 2 diabetes mellitus	1.21e-05	0.000346	CcSEcCtD
Irbesartan—Anxiety—Losartan—type 2 diabetes mellitus	1.21e-05	0.000345	CcSEcCtD
Irbesartan—Rash—Bromocriptine—type 2 diabetes mellitus	1.2e-05	0.000343	CcSEcCtD
Irbesartan—Dermatitis—Bromocriptine—type 2 diabetes mellitus	1.2e-05	0.000342	CcSEcCtD
Irbesartan—Tension—Ramipril—type 2 diabetes mellitus	1.2e-05	0.000342	CcSEcCtD
Irbesartan—Discomfort—Losartan—type 2 diabetes mellitus	1.2e-05	0.000342	CcSEcCtD
Irbesartan—Dysgeusia—Ramipril—type 2 diabetes mellitus	1.2e-05	0.000341	CcSEcCtD
Irbesartan—Headache—Bromocriptine—type 2 diabetes mellitus	1.19e-05	0.00034	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	1.19e-05	0.00034	CcSEcCtD
Irbesartan—Diarrhoea—Glyburide—type 2 diabetes mellitus	1.19e-05	0.00034	CcSEcCtD
Irbesartan—Nervousness—Ramipril—type 2 diabetes mellitus	1.19e-05	0.000338	CcSEcCtD
Irbesartan—Dry mouth—Losartan—type 2 diabetes mellitus	1.19e-05	0.000338	CcSEcCtD
Irbesartan—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	1.17e-05	0.000335	CcSEcCtD
Irbesartan—Paraesthesia—Metformin—type 2 diabetes mellitus	1.17e-05	0.000335	CcSEcCtD
Irbesartan—Muscle spasms—Ramipril—type 2 diabetes mellitus	1.17e-05	0.000335	CcSEcCtD
Irbesartan—Feeling abnormal—Orlistat—type 2 diabetes mellitus	1.17e-05	0.000334	CcSEcCtD
Irbesartan—Dyspnoea—Metformin—type 2 diabetes mellitus	1.17e-05	0.000333	CcSEcCtD
Irbesartan—Somnolence—Metformin—type 2 diabetes mellitus	1.16e-05	0.000332	CcSEcCtD
Irbesartan—Anaphylactic shock—Losartan—type 2 diabetes mellitus	1.16e-05	0.000331	CcSEcCtD
Irbesartan—Oedema—Losartan—type 2 diabetes mellitus	1.16e-05	0.000331	CcSEcCtD
Irbesartan—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	1.16e-05	0.000331	CcSEcCtD
Irbesartan—Infection—Losartan—type 2 diabetes mellitus	1.15e-05	0.000329	CcSEcCtD
Irbesartan—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	1.15e-05	0.000329	CcSEcCtD
Irbesartan—Dyspepsia—Metformin—type 2 diabetes mellitus	1.15e-05	0.000329	CcSEcCtD
Irbesartan—Tremor—Ramipril—type 2 diabetes mellitus	1.14e-05	0.000326	CcSEcCtD
Irbesartan—Shock—Losartan—type 2 diabetes mellitus	1.14e-05	0.000326	CcSEcCtD
Irbesartan—Urticaria—Valsartan—type 2 diabetes mellitus	1.14e-05	0.000326	CcSEcCtD
Irbesartan—Nervous system disorder—Losartan—type 2 diabetes mellitus	1.14e-05	0.000325	CcSEcCtD
Irbesartan—Thrombocytopenia—Losartan—type 2 diabetes mellitus	1.14e-05	0.000325	CcSEcCtD
Irbesartan—Decreased appetite—Metformin—type 2 diabetes mellitus	1.14e-05	0.000324	CcSEcCtD
Irbesartan—Abdominal pain—Valsartan—type 2 diabetes mellitus	1.14e-05	0.000324	CcSEcCtD
Irbesartan—Tachycardia—Losartan—type 2 diabetes mellitus	1.13e-05	0.000323	CcSEcCtD
Irbesartan—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	1.13e-05	0.000323	CcSEcCtD
Irbesartan—Nausea—Bromocriptine—type 2 diabetes mellitus	1.13e-05	0.000323	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	1.13e-05	0.000322	CcSEcCtD
Irbesartan—Fatigue—Metformin—type 2 diabetes mellitus	1.13e-05	0.000322	CcSEcCtD
Irbesartan—Urticaria—Orlistat—type 2 diabetes mellitus	1.13e-05	0.000322	CcSEcCtD
Irbesartan—Hyperhidrosis—Losartan—type 2 diabetes mellitus	1.12e-05	0.00032	CcSEcCtD
Irbesartan—Abdominal pain—Orlistat—type 2 diabetes mellitus	1.12e-05	0.00032	CcSEcCtD
Irbesartan—Body temperature increased—Orlistat—type 2 diabetes mellitus	1.12e-05	0.00032	CcSEcCtD
Irbesartan—Asthenia—Gliclazide—type 2 diabetes mellitus	1.12e-05	0.00032	CcSEcCtD
Irbesartan—Agitation—Ramipril—type 2 diabetes mellitus	1.12e-05	0.00032	CcSEcCtD
Irbesartan—Constipation—Metformin—type 2 diabetes mellitus	1.12e-05	0.000319	CcSEcCtD
Irbesartan—Angioedema—Ramipril—type 2 diabetes mellitus	1.12e-05	0.000318	CcSEcCtD
Irbesartan—Anorexia—Losartan—type 2 diabetes mellitus	1.11e-05	0.000316	CcSEcCtD
Irbesartan—Vomiting—Glyburide—type 2 diabetes mellitus	1.11e-05	0.000316	CcSEcCtD
Irbesartan—Pruritus—Gliclazide—type 2 diabetes mellitus	1.11e-05	0.000316	CcSEcCtD
Irbesartan—Malaise—Ramipril—type 2 diabetes mellitus	1.1e-05	0.000314	CcSEcCtD
Irbesartan—Rash—Glyburide—type 2 diabetes mellitus	1.1e-05	0.000313	CcSEcCtD
Irbesartan—Dermatitis—Glyburide—type 2 diabetes mellitus	1.1e-05	0.000313	CcSEcCtD
Irbesartan—Vertigo—Ramipril—type 2 diabetes mellitus	1.1e-05	0.000313	CcSEcCtD
Irbesartan—Syncope—Ramipril—type 2 diabetes mellitus	1.09e-05	0.000312	CcSEcCtD
Irbesartan—Leukopenia—Ramipril—type 2 diabetes mellitus	1.09e-05	0.000312	CcSEcCtD
Irbesartan—Headache—Glyburide—type 2 diabetes mellitus	1.09e-05	0.000311	CcSEcCtD
Irbesartan—Hypotension—Losartan—type 2 diabetes mellitus	1.09e-05	0.00031	CcSEcCtD
Irbesartan—Feeling abnormal—Metformin—type 2 diabetes mellitus	1.08e-05	0.000308	CcSEcCtD
Irbesartan—Loss of consciousness—Ramipril—type 2 diabetes mellitus	1.07e-05	0.000306	CcSEcCtD
Irbesartan—Diarrhoea—Gliclazide—type 2 diabetes mellitus	1.07e-05	0.000305	CcSEcCtD
Irbesartan—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	1.07e-05	0.000305	CcSEcCtD
Irbesartan—Cough—Ramipril—type 2 diabetes mellitus	1.06e-05	0.000304	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	1.06e-05	0.000302	CcSEcCtD
Irbesartan—Hypersensitivity—Valsartan—type 2 diabetes mellitus	1.06e-05	0.000302	CcSEcCtD
Irbesartan—Hypersensitivity—Orlistat—type 2 diabetes mellitus	1.05e-05	0.000298	CcSEcCtD
Irbesartan—Paraesthesia—Losartan—type 2 diabetes mellitus	1.04e-05	0.000298	CcSEcCtD
Irbesartan—Urticaria—Metformin—type 2 diabetes mellitus	1.04e-05	0.000296	CcSEcCtD
Irbesartan—Chest pain—Ramipril—type 2 diabetes mellitus	1.04e-05	0.000296	CcSEcCtD
Irbesartan—Arthralgia—Ramipril—type 2 diabetes mellitus	1.04e-05	0.000296	CcSEcCtD
Irbesartan—Myalgia—Ramipril—type 2 diabetes mellitus	1.04e-05	0.000296	CcSEcCtD
Irbesartan—Dyspnoea—Losartan—type 2 diabetes mellitus	1.04e-05	0.000295	CcSEcCtD
Irbesartan—Anxiety—Ramipril—type 2 diabetes mellitus	1.04e-05	0.000295	CcSEcCtD
Irbesartan—Nausea—Glyburide—type 2 diabetes mellitus	1.03e-05	0.000295	CcSEcCtD
Irbesartan—Abdominal pain—Metformin—type 2 diabetes mellitus	1.03e-05	0.000295	CcSEcCtD
Irbesartan—Dizziness—Gliclazide—type 2 diabetes mellitus	1.03e-05	0.000295	CcSEcCtD
Irbesartan—Somnolence—Losartan—type 2 diabetes mellitus	1.03e-05	0.000295	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	1.03e-05	0.000294	CcSEcCtD
Irbesartan—Asthenia—Valsartan—type 2 diabetes mellitus	1.03e-05	0.000294	CcSEcCtD
Irbesartan—Discomfort—Ramipril—type 2 diabetes mellitus	1.03e-05	0.000293	CcSEcCtD
Irbesartan—Dyspepsia—Losartan—type 2 diabetes mellitus	1.02e-05	0.000292	CcSEcCtD
Irbesartan—Asthenia—Orlistat—type 2 diabetes mellitus	1.02e-05	0.000291	CcSEcCtD
Irbesartan—Pruritus—Valsartan—type 2 diabetes mellitus	1.02e-05	0.00029	CcSEcCtD
Irbesartan—Dry mouth—Ramipril—type 2 diabetes mellitus	1.02e-05	0.00029	CcSEcCtD
Irbesartan—Decreased appetite—Losartan—type 2 diabetes mellitus	1.01e-05	0.000288	CcSEcCtD
Irbesartan—Pruritus—Orlistat—type 2 diabetes mellitus	1e-05	0.000287	CcSEcCtD
Irbesartan—Fatigue—Losartan—type 2 diabetes mellitus	1e-05	0.000286	CcSEcCtD
Irbesartan—Oedema—Ramipril—type 2 diabetes mellitus	9.96e-06	0.000284	CcSEcCtD
Irbesartan—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	9.96e-06	0.000284	CcSEcCtD
Irbesartan—Vomiting—Gliclazide—type 2 diabetes mellitus	9.94e-06	0.000284	CcSEcCtD
Irbesartan—Pain—Losartan—type 2 diabetes mellitus	9.93e-06	0.000283	CcSEcCtD
Irbesartan—Constipation—Losartan—type 2 diabetes mellitus	9.93e-06	0.000283	CcSEcCtD
Irbesartan—Rash—Gliclazide—type 2 diabetes mellitus	9.86e-06	0.000281	CcSEcCtD
Irbesartan—Dermatitis—Gliclazide—type 2 diabetes mellitus	9.85e-06	0.000281	CcSEcCtD
Irbesartan—Diarrhoea—Valsartan—type 2 diabetes mellitus	9.83e-06	0.00028	CcSEcCtD
Irbesartan—Shock—Ramipril—type 2 diabetes mellitus	9.8e-06	0.00028	CcSEcCtD
Irbesartan—Headache—Gliclazide—type 2 diabetes mellitus	9.79e-06	0.000279	CcSEcCtD
Irbesartan—Nervous system disorder—Ramipril—type 2 diabetes mellitus	9.77e-06	0.000279	CcSEcCtD
Irbesartan—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	9.75e-06	0.000278	CcSEcCtD
Irbesartan—Tachycardia—Ramipril—type 2 diabetes mellitus	9.72e-06	0.000277	CcSEcCtD
Irbesartan—Diarrhoea—Orlistat—type 2 diabetes mellitus	9.71e-06	0.000277	CcSEcCtD
Irbesartan—Skin disorder—Ramipril—type 2 diabetes mellitus	9.67e-06	0.000276	CcSEcCtD
Irbesartan—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	9.63e-06	0.000275	CcSEcCtD
Irbesartan—Feeling abnormal—Losartan—type 2 diabetes mellitus	9.57e-06	0.000273	CcSEcCtD
Irbesartan—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	9.5e-06	0.000271	CcSEcCtD
Irbesartan—Dizziness—Valsartan—type 2 diabetes mellitus	9.5e-06	0.000271	CcSEcCtD
Irbesartan—Anorexia—Ramipril—type 2 diabetes mellitus	9.49e-06	0.000271	CcSEcCtD
Irbesartan—Dizziness—Orlistat—type 2 diabetes mellitus	9.38e-06	0.000268	CcSEcCtD
Irbesartan—Asthenia—Metformin—type 2 diabetes mellitus	9.38e-06	0.000268	CcSEcCtD
Irbesartan—Hypotension—Ramipril—type 2 diabetes mellitus	9.31e-06	0.000266	CcSEcCtD
Irbesartan—Nausea—Gliclazide—type 2 diabetes mellitus	9.29e-06	0.000265	CcSEcCtD
Irbesartan—Pruritus—Metformin—type 2 diabetes mellitus	9.25e-06	0.000264	CcSEcCtD
Irbesartan—Urticaria—Losartan—type 2 diabetes mellitus	9.23e-06	0.000263	CcSEcCtD
Irbesartan—Abdominal pain—Losartan—type 2 diabetes mellitus	9.18e-06	0.000262	CcSEcCtD
Irbesartan—Body temperature increased—Losartan—type 2 diabetes mellitus	9.18e-06	0.000262	CcSEcCtD
Irbesartan—Vomiting—Valsartan—type 2 diabetes mellitus	9.13e-06	0.000261	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	9.07e-06	0.000259	CcSEcCtD
Irbesartan—Rash—Valsartan—type 2 diabetes mellitus	9.06e-06	0.000258	CcSEcCtD
Irbesartan—Dermatitis—Valsartan—type 2 diabetes mellitus	9.05e-06	0.000258	CcSEcCtD
Irbesartan—Vomiting—Orlistat—type 2 diabetes mellitus	9.02e-06	0.000257	CcSEcCtD
Irbesartan—Headache—Valsartan—type 2 diabetes mellitus	9e-06	0.000257	CcSEcCtD
Irbesartan—Diarrhoea—Metformin—type 2 diabetes mellitus	8.95e-06	0.000255	CcSEcCtD
Irbesartan—Rash—Orlistat—type 2 diabetes mellitus	8.95e-06	0.000255	CcSEcCtD
Irbesartan—Paraesthesia—Ramipril—type 2 diabetes mellitus	8.94e-06	0.000255	CcSEcCtD
Irbesartan—Dermatitis—Orlistat—type 2 diabetes mellitus	8.94e-06	0.000255	CcSEcCtD
Irbesartan—Headache—Orlistat—type 2 diabetes mellitus	8.89e-06	0.000254	CcSEcCtD
Irbesartan—Dyspnoea—Ramipril—type 2 diabetes mellitus	8.88e-06	0.000253	CcSEcCtD
Irbesartan—Somnolence—Ramipril—type 2 diabetes mellitus	8.85e-06	0.000253	CcSEcCtD
Irbesartan—Dyspepsia—Ramipril—type 2 diabetes mellitus	8.77e-06	0.00025	CcSEcCtD
Irbesartan—Decreased appetite—Ramipril—type 2 diabetes mellitus	8.66e-06	0.000247	CcSEcCtD
Irbesartan—Dizziness—Metformin—type 2 diabetes mellitus	8.65e-06	0.000247	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	8.6e-06	0.000245	CcSEcCtD
Irbesartan—Fatigue—Ramipril—type 2 diabetes mellitus	8.59e-06	0.000245	CcSEcCtD
Irbesartan—Hypersensitivity—Losartan—type 2 diabetes mellitus	8.56e-06	0.000244	CcSEcCtD
Irbesartan—Nausea—Valsartan—type 2 diabetes mellitus	8.53e-06	0.000243	CcSEcCtD
Irbesartan—Constipation—Ramipril—type 2 diabetes mellitus	8.52e-06	0.000243	CcSEcCtD
Irbesartan—Nausea—Orlistat—type 2 diabetes mellitus	8.43e-06	0.000241	CcSEcCtD
Irbesartan—Asthenia—Losartan—type 2 diabetes mellitus	8.33e-06	0.000238	CcSEcCtD
Irbesartan—Vomiting—Metformin—type 2 diabetes mellitus	8.32e-06	0.000237	CcSEcCtD
Irbesartan—Rash—Metformin—type 2 diabetes mellitus	8.25e-06	0.000235	CcSEcCtD
Irbesartan—Dermatitis—Metformin—type 2 diabetes mellitus	8.24e-06	0.000235	CcSEcCtD
Irbesartan—Pruritus—Losartan—type 2 diabetes mellitus	8.22e-06	0.000234	CcSEcCtD
Irbesartan—Feeling abnormal—Ramipril—type 2 diabetes mellitus	8.21e-06	0.000234	CcSEcCtD
Irbesartan—Headache—Metformin—type 2 diabetes mellitus	8.19e-06	0.000234	CcSEcCtD
Irbesartan—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	8.14e-06	0.000232	CcSEcCtD
Irbesartan—Diarrhoea—Losartan—type 2 diabetes mellitus	7.95e-06	0.000227	CcSEcCtD
Irbesartan—Urticaria—Ramipril—type 2 diabetes mellitus	7.91e-06	0.000226	CcSEcCtD
Irbesartan—Body temperature increased—Ramipril—type 2 diabetes mellitus	7.87e-06	0.000225	CcSEcCtD
Irbesartan—Abdominal pain—Ramipril—type 2 diabetes mellitus	7.87e-06	0.000225	CcSEcCtD
Irbesartan—Nausea—Metformin—type 2 diabetes mellitus	7.77e-06	0.000222	CcSEcCtD
Irbesartan—Dizziness—Losartan—type 2 diabetes mellitus	7.68e-06	0.000219	CcSEcCtD
Irbesartan—Vomiting—Losartan—type 2 diabetes mellitus	7.39e-06	0.000211	CcSEcCtD
Irbesartan—Hypersensitivity—Ramipril—type 2 diabetes mellitus	7.34e-06	0.000209	CcSEcCtD
Irbesartan—Rash—Losartan—type 2 diabetes mellitus	7.32e-06	0.000209	CcSEcCtD
Irbesartan—Dermatitis—Losartan—type 2 diabetes mellitus	7.32e-06	0.000209	CcSEcCtD
Irbesartan—Headache—Losartan—type 2 diabetes mellitus	7.28e-06	0.000208	CcSEcCtD
Irbesartan—Asthenia—Ramipril—type 2 diabetes mellitus	7.15e-06	0.000204	CcSEcCtD
Irbesartan—Pruritus—Ramipril—type 2 diabetes mellitus	7.05e-06	0.000201	CcSEcCtD
Irbesartan—Nausea—Losartan—type 2 diabetes mellitus	6.9e-06	0.000197	CcSEcCtD
Irbesartan—Diarrhoea—Ramipril—type 2 diabetes mellitus	6.81e-06	0.000194	CcSEcCtD
Irbesartan—Dizziness—Ramipril—type 2 diabetes mellitus	6.59e-06	0.000188	CcSEcCtD
Irbesartan—Vomiting—Ramipril—type 2 diabetes mellitus	6.33e-06	0.000181	CcSEcCtD
Irbesartan—Rash—Ramipril—type 2 diabetes mellitus	6.28e-06	0.000179	CcSEcCtD
Irbesartan—Dermatitis—Ramipril—type 2 diabetes mellitus	6.27e-06	0.000179	CcSEcCtD
Irbesartan—Headache—Ramipril—type 2 diabetes mellitus	6.24e-06	0.000178	CcSEcCtD
Irbesartan—Nausea—Ramipril—type 2 diabetes mellitus	5.92e-06	0.000169	CcSEcCtD
Irbesartan—CYP2C9—Metabolism—SLC9A1—type 2 diabetes mellitus	7.62e-07	3.4e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	7.59e-07	3.39e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—APOE—type 2 diabetes mellitus	7.59e-07	3.39e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP3A4—type 2 diabetes mellitus	7.59e-07	3.39e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	7.57e-07	3.38e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	7.55e-07	3.37e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.54e-07	3.37e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CETP—type 2 diabetes mellitus	7.53e-07	3.36e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.52e-07	3.36e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.51e-07	3.35e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—APOA1—type 2 diabetes mellitus	7.51e-07	3.35e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GLP1R—type 2 diabetes mellitus	7.48e-07	3.34e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GCG—type 2 diabetes mellitus	7.46e-07	3.33e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC2A4—type 2 diabetes mellitus	7.46e-07	3.33e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.32e-07	3.27e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.24e-07	3.23e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	7.16e-07	3.2e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.14e-07	3.19e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	7.1e-07	3.17e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	7.06e-07	3.15e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	7.06e-07	3.15e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	7.06e-07	3.15e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	7.02e-07	3.13e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PSMD6—type 2 diabetes mellitus	7e-07	3.13e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SREBF1—type 2 diabetes mellitus	7e-07	3.13e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SNAP25—type 2 diabetes mellitus	7e-07	3.13e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC2A2—type 2 diabetes mellitus	6.99e-07	3.12e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	6.93e-07	3.09e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CTGF—type 2 diabetes mellitus	6.87e-07	3.07e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	6.87e-07	3.07e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CPT1A—type 2 diabetes mellitus	6.84e-07	3.06e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MTR—type 2 diabetes mellitus	6.84e-07	3.06e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—type 2 diabetes mellitus	6.83e-07	3.05e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.81e-07	3.04e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.81e-07	3.04e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HMGCR—type 2 diabetes mellitus	6.81e-07	3.04e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SRC—type 2 diabetes mellitus	6.75e-07	3.01e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	6.72e-07	3e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	6.72e-07	3e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NAMPT—type 2 diabetes mellitus	6.71e-07	3e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	6.71e-07	3e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	6.67e-07	2.98e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—LIPC—type 2 diabetes mellitus	6.67e-07	2.98e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GCK—type 2 diabetes mellitus	6.67e-07	2.98e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HBA1—type 2 diabetes mellitus	6.67e-07	2.98e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ADRA2A—type 2 diabetes mellitus	6.66e-07	2.98e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP11A1—type 2 diabetes mellitus	6.63e-07	2.96e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARG—type 2 diabetes mellitus	6.61e-07	2.95e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.57e-07	2.93e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC9A1—type 2 diabetes mellitus	6.51e-07	2.91e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—INS—type 2 diabetes mellitus	6.49e-07	2.9e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	6.48e-07	2.89e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	6.48e-07	2.89e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	6.48e-07	2.89e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	6.48e-07	2.89e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	6.46e-07	2.88e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CETP—type 2 diabetes mellitus	6.43e-07	2.87e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GNB3—type 2 diabetes mellitus	6.43e-07	2.87e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.43e-07	2.87e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RELA—type 2 diabetes mellitus	6.41e-07	2.86e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP2E1—type 2 diabetes mellitus	6.4e-07	2.86e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HMOX1—type 2 diabetes mellitus	6.4e-07	2.86e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	6.39e-07	2.85e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	6.39e-07	2.85e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1A2—type 2 diabetes mellitus	6.33e-07	2.83e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC2A1—type 2 diabetes mellitus	6.33e-07	2.83e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CAT—type 2 diabetes mellitus	6.31e-07	2.82e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	6.23e-07	2.78e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	6.21e-07	2.77e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP3A4—type 2 diabetes mellitus	6.17e-07	2.76e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	6.14e-07	2.74e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—APOB—type 2 diabetes mellitus	6.13e-07	2.74e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	6.12e-07	2.73e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	6.12e-07	2.73e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	6.07e-07	2.71e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	6.07e-07	2.71e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.03e-07	2.69e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	6e-07	2.68e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	5.98e-07	2.67e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	5.98e-07	2.67e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	5.98e-07	2.67e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTM1—type 2 diabetes mellitus	5.96e-07	2.66e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ALB—type 2 diabetes mellitus	5.95e-07	2.66e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.91e-07	2.64e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	5.87e-07	2.62e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—LPL—type 2 diabetes mellitus	5.85e-07	2.61e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	5.82e-07	2.6e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—type 2 diabetes mellitus	5.79e-07	2.59e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.79e-07	2.58e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	5.77e-07	2.58e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	5.74e-07	2.56e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	5.73e-07	2.56e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	5.71e-07	2.55e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	5.69e-07	2.54e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3R1—type 2 diabetes mellitus	5.69e-07	2.54e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NOS3—type 2 diabetes mellitus	5.69e-07	2.54e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	5.56e-07	2.48e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	5.49e-07	2.45e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	5.47e-07	2.44e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.47e-07	2.44e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	5.41e-07	2.42e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.41e-07	2.42e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	5.39e-07	2.41e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.34e-07	2.39e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	5.28e-07	2.36e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	5.28e-07	2.36e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	5.28e-07	2.36e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.28e-07	2.36e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	5.28e-07	2.36e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	5.27e-07	2.35e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	5.25e-07	2.35e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—type 2 diabetes mellitus	5.25e-07	2.35e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	5.25e-07	2.34e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.23e-07	2.34e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	5.23e-07	2.34e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	5.21e-07	2.33e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—type 2 diabetes mellitus	5.2e-07	2.32e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	5.19e-07	2.32e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	5.19e-07	2.32e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	5.18e-07	2.31e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	5.18e-07	2.31e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	5.17e-07	2.31e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	5.15e-07	2.3e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	5.15e-07	2.3e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	5.15e-07	2.3e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	5.14e-07	2.29e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	5.11e-07	2.28e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SRC—type 2 diabetes mellitus	5.04e-07	2.25e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	5.03e-07	2.25e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	5.02e-07	2.24e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	5.01e-07	2.24e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	4.99e-07	2.23e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	4.97e-07	2.22e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	4.92e-07	2.2e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.91e-07	2.19e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	4.9e-07	2.19e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	4.89e-07	2.19e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	4.85e-07	2.17e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	4.85e-07	2.17e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—type 2 diabetes mellitus	4.84e-07	2.16e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	4.8e-07	2.15e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	4.76e-07	2.13e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	4.7e-07	2.1e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	4.69e-07	2.09e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	4.66e-07	2.08e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	4.65e-07	2.07e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—type 2 diabetes mellitus	4.64e-07	2.07e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	4.62e-07	2.06e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	4.62e-07	2.06e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	4.62e-07	2.06e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	4.56e-07	2.04e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—type 2 diabetes mellitus	4.54e-07	2.03e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	4.53e-07	2.02e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	4.52e-07	2.02e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	4.51e-07	2.01e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.51e-07	2.01e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	4.49e-07	2.01e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.47e-07	2e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	4.47e-07	2e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	4.47e-07	2e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	4.45e-07	1.99e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.42e-07	1.97e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	4.39e-07	1.96e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	4.39e-07	1.96e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	4.33e-07	1.93e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	4.29e-07	1.91e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	4.27e-07	1.91e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	4.26e-07	1.9e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	4.24e-07	1.89e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	4.22e-07	1.89e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	4.21e-07	1.88e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.19e-07	1.87e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	4.19e-07	1.87e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	4.17e-07	1.86e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	4.17e-07	1.86e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	4.15e-07	1.85e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	4.11e-07	1.84e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	4.07e-07	1.82e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	4.07e-07	1.82e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	4.04e-07	1.8e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	4.03e-07	1.8e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	4.01e-07	1.79e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	4e-07	1.79e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	4e-07	1.79e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	3.99e-07	1.78e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	3.98e-07	1.78e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	3.98e-07	1.78e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	3.97e-07	1.77e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	3.95e-07	1.76e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	3.87e-07	1.73e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	3.84e-07	1.72e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	3.82e-07	1.71e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	3.67e-07	1.64e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	3.67e-07	1.64e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	3.66e-07	1.64e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	3.59e-07	1.61e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	3.51e-07	1.57e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	3.48e-07	1.55e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	3.48e-07	1.55e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	3.45e-07	1.54e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.45e-07	1.54e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	3.44e-07	1.54e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	3.43e-07	1.53e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	3.42e-07	1.53e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	3.41e-07	1.52e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	3.41e-07	1.52e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—type 2 diabetes mellitus	3.4e-07	1.52e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	3.39e-07	1.51e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	3.37e-07	1.51e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	3.36e-07	1.5e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	3.29e-07	1.47e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	3.2e-07	1.43e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	3.15e-07	1.41e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	3.14e-07	1.4e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.13e-07	1.4e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	3.13e-07	1.4e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	3.07e-07	1.37e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.06e-07	1.37e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	3.02e-07	1.35e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	3.02e-07	1.35e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	2.99e-07	1.34e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	2.99e-07	1.34e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	2.98e-07	1.33e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	2.97e-07	1.33e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	2.95e-07	1.32e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	2.91e-07	1.3e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	2.83e-07	1.26e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	2.77e-07	1.24e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	2.76e-07	1.23e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	2.74e-07	1.22e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	2.69e-07	1.2e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	2.67e-07	1.19e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	2.64e-07	1.18e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	2.63e-07	1.18e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—type 2 diabetes mellitus	2.62e-07	1.17e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	2.6e-07	1.16e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	2.56e-07	1.14e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	2.56e-07	1.14e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	2.34e-07	1.04e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.29e-07	1.02e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.25e-07	1e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.06e-07	9.21e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	1.97e-07	8.81e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	1.97e-07	8.81e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	1.8e-07	8.06e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	1.69e-07	7.54e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.39e-07	6.19e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	1.37e-07	6.14e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	1.17e-07	5.25e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	9.07e-08	4.05e-06	CbGpPWpGaD
